Abstract: Described here is a method for reducing or preventing Pseudomonas aeruginosa biofilm formation in a human subject in need thereof, comprising administering to the human subject a first composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage. Also described is an antigen-binding polypeptide that binds specifically to a CoaB protein of Pf-family bacteriophage or fragment thereof.
Type:
Grant
Filed:
October 8, 2020
Date of Patent:
February 27, 2024
Assignee:
INIMMUNE CORPORATION
Inventors:
Paul L. Bollyky, William Parks, Patrick Secor
Abstract: Toll-like receptor (TLR) ligands having an allose-based core are stable in aqueous formulation and are useful in treating, preventing, or reducing susceptibility to diseases or conditions mediated by TLRs, such as cancer, infectious disease, allergy, autoimmune disease, sepsis, and ischemia reperfusion.
Type:
Grant
Filed:
February 12, 2019
Date of Patent:
October 4, 2022
Assignee:
INIMMUNE CORPORATION
Inventors:
Helene Bazin-Lee, George Ettenger, Juhienah Khalaf, Kendal T. Ryter
Abstract: Described here is a method for reducing or preventing Pseudomonas aeruginosa biofilm formation in a human subject in need thereof, comprising administering to the human subject a first composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage. Also described is an antigen-binding polypeptide that binds specifically to a CoaB protein of Pf-family bacteriophage or fragment thereof.
Type:
Grant
Filed:
January 30, 2019
Date of Patent:
November 17, 2020
Assignee:
INIMMUNE CORPORATION
Inventors:
Paul L. Bollyky, William Parks, Patrick Secor